Outlook Therapeutics prices $55m offering at $0.99; the stock closes below the deal price

by Adam Kowalczyk · August 13, 2026

Filings & Deals Reporter, The MicroCap Herald

Outlook Therapeutics priced a $55.0 million underwritten public offering before Thursday's open, and by the closing bell its shares were trading below the price the new buyers paid. According to the company's press release distributed through GlobeNewswire, Outlook sold 55,555,556 shares of common stock with accompanying warrants at a combined public offering price of $0.99 per share and accompanying warrant, for aggregate gross proceeds of roughly $55.0 million before underwriting discounts and expenses. The common stock trades on Nasdaq under the symbol OTLK.

The warrants are the part of the structure that matters most to existing holders. Each share sold carries one warrant, exercisable immediately, with an exercise price of $1.10 per share and a five-year term, the release said. That means the deal creates up to 55,555,556 additional shares beyond the 55,555,556 being issued at closing, at a strike set exactly at Wednesday's $1.10 closing price. The underwriters also received a 30-day option to buy up to 8,333,333 additional shares and/or warrants to purchase an equivalent number of shares, at the public offering price less underwriting discounts.

Piper Sandler and BTIG are acting as joint bookrunning managers, with Brookline Capital Markets, a division of Arcadia Securities, as lead manager, according to the release. Closing is expected on August 14, 2026, subject to customary conditions. Outlook said it intends to use the net proceeds from the offering, "together with existing cash and cash equivalents, to support the commercial launch of LYTENAVA™ in the United States, as well as for working capital and general corporate purposes."

The dilution arithmetic is straightforward and large. StockAnalysis.com listed 187.00 million shares outstanding for OTLK on Thursday, a count that predates the offering's expected August 14 closing, and a market capitalization of $166.20 million at the $0.8888 close. The 55,555,556 shares being issued at closing therefore represent roughly a 30 percent increase in the share count before a single warrant is exercised. Layer on the 55,555,556 warrant shares, the 8,333,333 over-allotment shares and warrants for a further 8,333,333, and the deal could ultimately produce about 127.8 million new shares — more than two-thirds again the pre-deal count. Existing common holders are diluted by all of it, and common equity sits behind the company's debt in any adverse scenario.

The reason the raise happened at a discount is visible in the company's own filings. In a Form 8-K accepted by the SEC on August 12, 2026 — the day before the pricing — Outlook disclosed preliminary, unaudited cash and cash equivalents of approximately $11.2 million as of June 30, 2026, and stated in its risk-factor disclosure that there is substantial doubt about its ability to continue as a going concern, and that its cash resources would only be sufficient to fund operations into September 2026. The same filing traced how the company got there: $7.7 million of cash at March 31, 2026, supplemented by roughly $4.2 million of net proceeds from an April equity offering and $4.9 million from a May offering.

Debt sits on top of that. Per the August 12 filing, Outlook had $19.8 million outstanding as of March 31, 2026 under an unsecured note issued to Atlas Sciences LLC in March 2026. The note bears interest at the prime rate plus 3 percent, with a floor of 9.5 percent, and matures on June 16, 2027. The holder has quarterly redemption rights of up to $3.0 million beginning in September 2026, and a 7.5 percent exit fee applies to cash payments. In other words, the first redemption window opens in the same month the company had said its cash would run out.

The commercial backdrop is genuinely new. The FDA approved LYTENAVA (bevacizumab-vikg) on July 24, 2026 for the treatment of neovascular, or wet, age-related macular degeneration in adults, according to the same 8-K, adding a US approval to existing clearances in the European Union and the United Kingdom. A US launch costs money — sales force, distribution, inventory, reimbursement work — which is precisely what Thursday's proceeds are earmarked for. Approval and funding are not the same thing, and this raise is the second half of that equation.

The market's reaction was unambiguous. Shares closed at $0.8888, down $0.2112 or 19.20 percent from Wednesday's $1.10 close, according to StockAnalysis.com. RTTNews, reporting at 11:36 a.m. ET with the stock at $0.84, put the range to that point in the session at $0.76 to $0.85 on volume of 36.76 million shares against an average of 22.43 million, and noted a 52-week range of $0.16 to $3.39. Quiver Quantitative, summarizing the deal, flagged the offering price itself as the signal, noting that all the securities are being sold by the company rather than by existing holders.

That leaves the warrants meaningfully out of the money on day one. A $1.10 strike against an $0.8888 close means the warrant holders need roughly a 24 percent recovery in the common stock before exercise is rational, and the company gets no incremental cash from those warrants until that happens. Five-year warrants at a fixed strike also sit as a persistent supply overhang above the current price: every rally toward $1.10 carries the possibility of new shares being created into it.

Two further risks are worth stating plainly. First, Nasdaq's continued-listing standards require a minimum closing bid price of $1.00; Outlook closed below that level on Thursday, and while the company has not disclosed receiving any bid-price deficiency notice, a deficiency is only triggered after 30 consecutive business days below the threshold. Second, the going-concern conclusion disclosed on August 12 was made before this raise settled, and the company has not yet published a revised runway. Outlook is scheduled to report fiscal third-quarter results and host a corporate update call on August 14, 2026 — the same day the offering is expected to close — which is the first place a restated cash figure would appear.

Nothing in this article is a recommendation. Micro-cap biotechs that fund commercial launches through discounted equity carry compounding risks: dilution from the shares themselves, overhang from the warrants, refinancing risk on the Atlas note, and the possibility of further raises if the launch ramps slower than planned.